Oxcarbazepine Tablet, Film Coated
Product Images NDC 68462-138

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 68462-138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl150mg500

Label for Oxcarbazepine Tablets, USP 150 mg film-coated tablets, oral use, containing 500 tablets per bottle. Labeler is Glenmark Pharmaceuticals Inc., USA. Includes storage instructions and pharmacist dispensing note, with barcode and manufacturing details from Glenmark Pharmaceuticals Limited, India.*

FDA Label Image

Lbl300mg500

Oxcarbazepine Tablets, USP 300 mg film-coated oral tablets in a 500-tablet package, labeled for prescription use only. The label includes storage instructions and manufacturer information for Glenmark Pharmaceuticals Inc., USA.*

FDA Label Image

Lbl600mg500

Oxcarbazepine Tablets, USP 600 mg film-coated tablets label from Glenmark Pharmaceuticals Inc. The label states the quantity as 500 tablets and instructs pharmacists to dispense the medication guide separately. Storage conditions and dosage instructions are included, along with manufacturer information for Glenmark Pharmaceuticals Limited in India and Glenmark Pharmaceuticals Inc. in the USA.*

FDA Label Image

Figure1

A Kaplan-Meier survival curve graph comparing Oxcarbazepine and placebo treatment groups over time from day 2 to day 11. The y-axis shows the event rate, and the x-axis shows the time on trial in days. The solid line represents Oxcarbazepine, and the dashed line represents placebo, with a p-value of 0.0001 from a log-rank test displayed on the graph.*

FDA Label Image

Figure2

A line graph showing seizure rate over time from first dose to first seizure for Oxcarbazepine versus placebo. The seizure rate is plotted on the y-axis, and treatment duration in days on the x-axis. The graph includes a log-rank test p-value of 0.046 comparing the two groups.*

FDA Label Image

Figure3

A Kaplan-Meier survival curve graph showing time to exit (days) on the x-axis and exit rate on the y-axis. Two groups, labeled as 'High' and 'Low,' are compared with a log-rank test resulting in a p-value of 0.0001, indicating a significant difference between their exit rates over time.*

FDA Label Image

Figure4

A Kaplan-Meier plot showing the exit rate over time in days for two treatment groups labeled as HIGH and LOW. The y-axis represents the exit rate from 0.0 to 1.0, and the x-axis represents time to exit in days up to 130 days. A statistical annotation indicates a log-rank test with a p-value of 0.0001, suggesting a significant difference between the two groups' exit rates.*

FDA Label Image

Logo

FDA Label Image

Structure

Chemical structure diagram of Oxcarbazepine, showing its molecular framework featuring phenyl rings and amide functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.